Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus.
Osteoporosis is often present in postmenopausal women. The aim of this retrospective cohort study was to assess the cumulative incidence and predictive factors for bone fracture after cessation of interferon (IFN) in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus (HCV). A total of 420 postmenopausal women treated with IFN monotherapy were enrolled. The mean observation period was 7.2 years. The primary goal was the development of bone fracture. Evaluation was carried out by using the Kaplan-Meier method and the Cox proportional hazards analysis. Thirty-one out of 420 patients sustained bone fracture. The cumulative development rate of bone fracture was 3.6% at 5th year, 9.2% at 10th year, and 17.4% at 15th year. Multivariate Cox proportional hazards analysis showed that bone fracture after cessation of IFN therapy occurred when histological staging of the liver was advanced (hazard ratio (HR): 2.54; 95% confidence interval (CI) = 1.21-5.31; P = 0.013), serum albumin level was < 3.5g/dl (HR: 2.25; 95% CI = 1.10-4.59; P = 0.026), and virus clearance was not achieved (HR: 3.65; 95% CI = 1.11-12.05; P = 0.033). The results indicate that virus clearance causes a reduction of two-thirds in the risk of bone fracture after cessation of IFN therapy in postmenopausal women with osteoporosis and chronic liver disease caused by HCV. J. Med. Virol. 82:390-395, 2010. (c) 2010 Wiley-Liss, Inc.
Arase
Yasuji
Y
Department of Hepatology and Okinaka Memorial Institute for Medical Research Toranomon Hospital, Tokyo, Japan. es9y-ars@asahi-net.or.jp
Suzuki
Fumitaka
F
Suzuki
Yoshiyuki
Y
Akuta
Norio
N
Kobayashi
Masahiro
M
Sezaki
Hitomi
H
Hosaka
Tetsuya
T
Kawamura
Yusuke
Y
Yatsuji
Hiromi
H
Hirakawa
Miharu
M
Ikeda
Kenji
K
Hsieh
Shiun Dong
SD
Oomoto
Yuki
Y
Amakawa
Kazuhisa
K
Kato
Hisahito
H
Kazawa
Tamae
T
Tsuji
Hiroshi
H
Kobayashi
Tetsuro
T
Kumada
Hiromitsu
H
D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D015331:Cohort Studies; D005260:Female; D050723:Fractures, Bone / Q000453:epidemiology*; D016174:Hepacivirus / Q000302:isolation & purification*; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D006801:Humans; D015994:Incidence; D007372:Interferons / Q000627:therapeutic use; D008099:Liver / Q000473:pathology; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications*; D017698:Postmenopause; D012189:Retrospective Studies; D019562:Viral Load
D000998:Antiviral Agents; D007372:Interferons